Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation
This article was originally published in The Tan Sheet
Executive Summary
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
You may also be interested in...
In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers
Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.
In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers
Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.
Petitions Denied For ‘Pharmacist Category’ Nonprescription Viagra, Lipitor, Chantix
The petitioner offers no evidence to support establishing a “Pharmacists Category of Drugs Behind the Counter” status for nonprescription sales with continued Rx distribution of Viagra, Lipitor, Narcan and Chantix, CDER Director Woodcock says in rejecting a petition on each drug.